Idiopathic

News

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic ...

Published December 1, 2008, 12:00 pm, PR Newswire via Yahoo! Finance

S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis .

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

australia

Related Idiopathic Stories

From Various News Sources

No related news stories found.

Related Social Bookmarks

None found at this time.


News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a